Navigation Links
Isis Pharmaceuticals to Receive $7.5 Million from Alnylam
Date:1/13/2014

CARLSBAD, Calif., Jan. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will receive $7.5 million from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from the recently announced alliance between Genzyme and Alnylam.  In addition, Isis has the potential to receive royalties on products and a portion of future milestone payments.  This transaction underscores the value of Isis' innovation and the leadership role Isis has played in the field of nucleic acid based therapeutics.

(Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO)

"Our innovation in RNA-based drug discovery has enabled us to create a broad and extensive patent position that covers many key discoveries for the RNA therapeutic space.  The breadth and depth of our patent estate has allowed us to create a number of relationships, such as the one we have with Alnylam, that enhance our leadership in the field.  Our technology supports RNA-based drug discovery efforts for us and our partners and allows our partners access to our technology. To date we have generated well over $400 million from the sales and licensing of our intellectual property, including more than $50 million from Alnylam's collaborations," said B. Lynne Parshall, chief operating officer at Isis.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 31 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States for the treatment of patients with HoFH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis Pharmaceuticals' business, its intellectual property portfolio, and the therapeutic and commercial potential of the Company's technologies. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO® is a registered trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals Estimates Fourth Quarter and Full Year 2013 Product Revenue and Provides Full Year 2014 Revenue Guidance
2. Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness
3. Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information
4. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aegerion Pharmaceuticals, Inc.
5. Crealta Pharmaceuticals LLC Announces Completion of the Acquisition of Substantially All of the Assets of Savient Pharmaceuticals, Inc.
6. Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704
7. Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
8. Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
9. Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
10. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
11. Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016  Today, Simpson Healthcare Executives, a global leader ... selected as winners of multiple awards at the 2016 ... the PLATINUM level, Blue Zones Menu at the GOLD ... Level, and our proprietary 3ConneX Platform at the HONORABLE ... we are excited to showcase our new Platinum and ...
(Date:12/2/2016)... bioLytical Laboratories (das "Unternehmen"), ein Weltführer bei schnellen ... HIV-Selbsttests  in einer Version mit geringeren Kosten einzuführen.  ... ... New: INSTI Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444833 ) ...
(Date:11/30/2016)... DUBLIN , Nov 30, 2016 Research ... for Intracranial Pressure Monitoring Devices 2017 - MedCore" report to their ... , , ... the brain and the skull. In healthy individuals, it is circulated though ... there are cases where the amount of CSF surrounding the brain changes ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change ... Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch ... plan (Part D) need to make changes during this period order for their new ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... More ... school and while 84 percent of parents report speaking with their child about sex ... and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
(Date:12/2/2016)... ... December 02, 2016 , ... On November 24th, ... families from eight different sites throughout Miami-Dade and Broward counties. This is the ... very hard on Thanksgiving morning by putting together individual meals via assembly lines ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge dentists, Dr. ... plan for all patients. Understanding that budget can play a part in oral ... of perks, including discounts on many valuable dental treatments. Options for individuals, couples, ...
Breaking Medicine News(10 mins):